Date published: 2025-10-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

4-Aminopyridine (CAS 504-24-5)

5.0(2)
Write a reviewAsk a question

See product citations (3)

Alternate Names:
4-Pyridinamine; Fampridine
Application:
4-Aminopyridine is a nonselective K+ channel blocker that binds from the cytoplasmic side of the cell membrane
CAS Number:
504-24-5
Purity:
≥98%
Molecular Weight:
94.11
Molecular Formula:
C5H6N2
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

4-Aminopyridine (4-AP) is a nonselective K+ channel blocker that has been used to characterize and study the blockage of K+ channels. Studies show that 4-Aminopyridine binds from the cytoplasmic side of the cell membrane. Research suggests that 4-Aminopyridine extends the potentials of unmyelinated and demyelinated fibers, facilitates conduction in fibers blocked by demyelination, and can induce glutamate and neurotransmitter gamma-aminobutyric acid (GABA) release.


4-Aminopyridine (CAS 504-24-5) References

  1. Different state dependencies of 4-aminopyridine binding to rKv1.4 and rKv4.2: role of the cytoplasmic halves of the fifth and sixth transmembrane segments.  |  Tseng, GN. 1999. J Pharmacol Exp Ther. 290: 569-77. PMID: 10411564
  2. (4-Aminopyridine-kappaN1)(phthalocyaninato-kappa4N)zinc(II) tetrahydrofuran disolvate.  |  Yang, FJ., et al. 2008. Acta Crystallogr C. 64: m375-7. PMID: 18989080
  3. [4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis].  |  Husseini, L., et al. 2010. Nervenarzt. 81: 203-11. PMID: 20112006
  4. Regional differences in nerve terminal Na+ channel subtype expression and Na+ channel-dependent glutamate and GABA release in rat CNS.  |  Westphalen, RI., et al. 2010. J Neurochem. 113: 1611-20. PMID: 20374421
  5. 4-aminopyridine: new life for an old drug.  |  Hauser, SL. and Johnston, SC. 2010. Ann Neurol. 68: A8-9. PMID: 20583227
  6. 4-aminopyridine and cerebellar gait: a retrospective case series.  |  Schniepp, R., et al. 2012. J Neurol. 259: 2491-3. PMID: 22760944
  7. 4-aminopyridine toxicity: a case report and review of the literature.  |  King, AM., et al. 2012. J Med Toxicol. 8: 314-21. PMID: 22782458
  8. Can 4-aminopyridine modulate dysfunctional gait networks in Parkinson's disease?  |  Luca, CC. and Singer, C. 2013. Parkinsonism Relat Disord. 19: 777-82. PMID: 23706539
  9. Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond.  |  Leussink, VI., et al. 2018. CNS Drugs. 32: 637-651. PMID: 29992409
  10. 4-aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect - No.  |  Göbel, K. and Wiendl, H. 2020. Mult Scler. 26: 1311-1312. PMID: 32628061
  11. Neuroprotective Properties of 4-Aminopyridine.  |  Dietrich, M., et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8: PMID: 33653963
  12. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres.  |  Sherratt, RM., et al. 1980. Nature. 283: 570-2. PMID: 7354839
  13. Closed- and open-state binding of 4-aminopyridine to the cloned human potassium channel Kv1.5.  |  Bouchard, R. and Fedida, D. 1995. J Pharmacol Exp Ther. 275: 864-76. PMID: 7473178

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

4-Aminopyridine, 25 g

sc-202421
25 g
$37.00

4-Aminopyridine, 100 g

sc-202421A
100 g
$120.00

4-Aminopyridine, 1 kg

sc-202421B
1 kg
$1132.00